Life sciences
Why strong life sciences companies still lose SBIR awards
Good science is not enough. The recurring reasons life sciences applications score badly, from preliminary data gaps to regulatory hand-waving.
Preliminary data below the study section bar
Life sciences reviewers apply an informal evidence threshold that is rarely written down. A therapeutic program with no in vivo signal, or a diagnostic with no clinical sample data, is usually judged premature regardless of the mechanism.
Where data is thin, the honest fix is to narrow the claim rather than widen the hedging. A tightly scoped feasibility aim on solid ground scores better than an ambitious plan on thin ground.
The regulatory paragraph everyone skips
A single vague sentence about future FDA engagement tells reviewers you have not thought about it. Name the likely pathway, the classification you expect, and the studies that pathway will require.
If a pre-submission meeting has happened, say so and summarize the feedback. It is one of the strongest credibility signals available to an early-stage company.
Team gaps that are visible from outside
A founding team of scientists with no clinical, regulatory or commercial voice reads as incomplete. Reviewers are assessing whether this group can convert science into a product.
Named advisors with defined roles and budgeted time close the gap credibly. An unpaid list of famous names does not.
Choosing the wrong door
Platform companies frequently apply to an institute whose mission fits one downstream application while the proposal describes the general platform. The result is an application nobody feels ownership of.
Pick the indication, write to that institute's mission, and keep the platform as the reason you can win the next award too.
Want this checked against your own project?
Book a free consultation and we'll tell you honestly whether your technology fits NSF SBIR, and which program gives you the best chance.
Book Free Consultation